Clinical Trials Logo

Disease Exacerbation clinical trials

View clinical trials related to Disease Exacerbation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02661191 Completed - Asthma Clinical Trials

Vitamin D Deficiency and Asthma Exacerbation

AVD
Start date: October 2012
Phase: N/A
Study type: Interventional

The study aim is in two phases. First phase: to evaluate the influence of vitamin D deficiency on asthma severity, degree of airway obstruction and frequency of asthma exacerbations. Second phase: to evaluate if in patients with vitamin D deficiency (25-OH vitamin D levels below 20 ng/ml), vitamin D supplementation decreases the number of disease exacerbations.

NCT ID: NCT02439372 Completed - Ulcerative Colitis Clinical Trials

Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis

ACE-UC
Start date: April 2015
Phase:
Study type: Observational

Consequences of latent cytomegalovirus (CMV) infection reactivation on ulcerative colitis flare, as a flare-worsening factor or simple bystander, are debated. Theoretically, CMV-specific cell-mediate immune response will further categorize the patients into high or low risk of CMV colitis. The investigators thus evaluate the usefulness of CMV-specific ELISPOT assay in patient with ulcerative colitis flare to assess the the impact of CMV colitis on ulcerative colitis flare.

NCT ID: NCT00876577 Completed - Chronic Bronchitis Clinical Trials

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

VICTOR
Start date: May 2009
Phase: N/A
Study type: Observational

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).